https://scholars.lib.ntu.edu.tw/handle/123456789/517572
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Wu N.-L. | en_US |
dc.contributor.author | Hsu C.-J. | en_US |
dc.contributor.author | Sun F.-J. | en_US |
dc.contributor.author | TSEN-FANG TSAI | en_US |
dc.creator | Wu N.-L.;Hsu C.-J.;Sun F.-J.;Tsen-Fang Tsai | - |
dc.date.accessioned | 2020-10-22T07:27:49Z | - |
dc.date.available | 2020-10-22T07:27:49Z | - |
dc.date.issued | 2017 | - |
dc.identifier.issn | 0385-2407 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85019100290&doi=10.1111%2f1346-8138.13900&partnerID=40&md5=93f27546ca0e2bb0693401860735038f | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/517572 | - |
dc.description.abstract | The efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, has been evaluated for moderate to severe plaque psoriasis in global trials which have included a low proportion of Asian subjects. We analyzed the efficacy and safety of secukinumab in Taiwanese patients in a phase III global clinical trial (ERASURE). Fifty-one Taiwanese patients were randomized into s.c. placebo, 150 and 300 mg secukinumab treatment groups. The proportions of patients who achieved 75% or more improvement in Psoriasis Area and Severity Index (PASI-75) at week 12 were 87.5% with 300 mg secukinumab, 70% with 150 mg secukinumab, 0% with placebo. Of the patients receiving 300 mg secukinumab, 68.8% achieved PASI-90 at week 12. Analysis of overall patients receiving 300 mg secukinumab for 12 weeks showed that the proportion of PASI-75 responders was less in patients with body mass index of 25 or more than less than 25. During the entire 52 weeks, the incidence of adverse events (AE) was consistent with the overall population in ERASURE. The most common AE (cases/per 100 patient-year) during the entire treatment period were upper respiratory tract infection and pruritus. The duration of upper respiratory tract infection per 100 patient-year was approximately 399 days in placebo, 1261 days in 150 mg secukinumab and 1805 days in 300 mg secukinumab. The safety and efficacy of secukinumab in Taiwanese patients was compatible with the global phase III study in the treatment of moderate to severe plaque psoriasis. ? 2017 Japanese Dermatological Association | - |
dc.publisher | Blackwell Publishing Ltd | - |
dc.relation.ispartof | Journal of Dermatology | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | placebo; secukinumab; biological product; dermatological agent; IL17A protein, human; interleukin 17; monoclonal antibody; secukinumab; adult; Article; body mass; controlled study; disease duration; disease severity; double blind procedure; drug efficacy; drug safety; female; human; major clinical study; male; phase 3 clinical trial; pruritus; Psoriasis Area and Severity Index; psoriasis vulgaris; randomized controlled trial; Taiwanese; treatment response; upper respiratory tract infection; antagonists and inhibitors; Asian continental ancestry group; clinical trial; dose response; middle aged; multicenter study; psoriasis; severity of illness index; subcutaneous drug administration; Taiwan; treatment outcome; Adult; Antibodies, Monoclonal; Asian Continental Ancestry Group; Biological Products; Dermatologic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Injections, Subcutaneous; Interleukin-17; Male; Middle Aged; Psoriasis; Severity of Illness Index; Taiwan; Treatment Outcome | - |
dc.title | Efficacy and safety of secukinumab in Taiwanese patients with moderate to severe plaque psoriasis: Subanalysis from ERASURE phase III study | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1111/1346-8138.13900 | - |
dc.identifier.pmid | 28493369 | - |
dc.identifier.scopus | 2-s2.0-85019100290 | - |
dc.relation.pages | 1129-1137 | - |
dc.relation.journalvolume | 44 | - |
dc.relation.journalissue | 10 | - |
item.fulltext | no fulltext | - |
item.grantfulltext | none | - |
item.openairetype | journal article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | Dermatology | - |
crisitem.author.dept | Dermatology-NTUH | - |
crisitem.author.orcid | 0000-0002-1498-1474 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。